恩格列净、2型糖尿病患者的心血管结局及死亡率 - Suppr

Suppr

超能文献

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

作者信息

Edwards Jonathan L

机构信息

Summa Health System, Akron, OH

出版信息

N Engl J Med. 2016 Mar 17;374(11):1093. doi: 10.1056/NEJMc1600827.

DOI:10.1056/NEJMc1600827

PMID:26981943

Abstract

摘要

相似文献

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1093. doi: 10.1056/NEJMc1600827.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1092-3. doi: 10.1056/NEJMc1600827.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1092. doi: 10.1056/NEJMc1600827.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827.

Preventing cardiovascular events with empagliflozin: at what cost?

Lancet Diabetes Endocrinol. 2015 Dec;3(12):931. doi: 10.1016/S2213-8587(15)00439-8.

ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.

Ann Intern Med. 2016 Jan 19;164(2):JC2. doi: 10.7326/ACPJC-2016-164-2-002.

In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.

Am Fam Physician. 2016 Mar 1;93(5):410.

[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].

Praxis (Bern 1994). 2016 Mar 16;105(6):349-50. doi: 10.1024/1661-8157/a002288.

The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.

Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11.

引用本文的文献

Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon.

Sleep Breath. 2023 Mar;27(1):77-89. doi: 10.1007/s11325-022-02606-1. Epub 2022 Apr 4.

Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease.

Pharmaceuticals (Basel). 2021 Jul 30;14(8):751. doi: 10.3390/ph14080751.

Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus.

J Am Heart Assoc. 2021 Aug 3;10(15):e019437. doi: 10.1161/JAHA.120.019437. Epub 2021 Jul 26.

The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.

Cell Signal. 2021 Jan;77:109825. doi: 10.1016/j.cellsig.2020.109825. Epub 2020 Nov 4.

Disruption of energy utilization in diabetic cardiomyopathy; a mini review.

Curr Opin Pharmacol. 2020 Oct;54:82-90. doi: 10.1016/j.coph.2020.08.015. Epub 2020 Sep 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验